Pathogenesis and screening for hepatocellular carcinoma

Clinics in Liver Disease

Volumn 8, Issue 2, 2004, Pages 419-443

  Sherman, Morris ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; LAMIVUDINE; TUMOR MARKER;

ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CELL CLONING; CELL POPULATION; CHRONIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DYSPLASIA; ECHOGRAPHY; FOLLOW UP; GENETIC RISK; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER TRANSPLANTATION; MODEL; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; RISK ASSESSMENT; SERODIAGNOSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL TIME; TREATMENT PLANNING; TUMOR BIOPSY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 2942528989     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.02.002     Document Type: Review

References (105)

1. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124(11):1599-607.
2. Nakashima E, Wanless IR. Most non-cirrhotic livers with hepatocellular carcinoma (HCC) have evidence of fibrosis or regressed cirrhosis: implications for the pathogenesis of HCC. Hepatology 1999;30:257A.
3. Donato F, Gelatti U, Chiesa R, Albertini A, Bucella E, Boffetta P, et al. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 1999;10:417-21.
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al, Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
5. Matsumoto K, Yoshimoto J, Sugo H, Kojima K, Futagawa S, Matsumoto T. Relationship between the histological degrees of hepatitis and the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis C. Hepatol Res 2002;23:196-201.
6. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis C-virus infection. Lancet 1998;351:1773-7.
7. Wee A, Yap I, Guan R. Hepatocyte hepatitis B surface antigen expression in chronic hepatitis B virus carriers in Singapore: correlation with viral replication and liver pathology. J Gastroenterol Hepatol 1991;6:466-70.
8. Yasui H, Hino O, Ohtake K, Machinami R, Kitagawa T. Clonal growth of hepatitis B virusintegrated hepatocytes in cirrhotic liver nodules. Cancer Res 1992;52:6810-4.
9. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996;111:455-61.
10. Anthony PP. Liver cell dysplasia: what is its significance? Hepatology 1987;7:394-5.
11. Watanabe S, Okita K, Harada T. Morphologic studies of the liver cell dysplasia. Cancer 1983;51:2197-205.
12. Hytiroglou P, Theise ND, Schwartz M, Mor E, Miller C, Thung SN. Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology 1995;21:703-8.
13. Ueda K, Terada T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: A morphometric study. Hum Pathol 1992;23:619-26.
14. Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986;91:198-208.
15. Ballardini G, Groff P, Zoli M, Bianchi G, Giostra F, Francesconi R, et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994;20:218-22.
16. Borzio M, Trere D, Borzio F, Ferrari AR, Bruno S, Roncalli M, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998;510:96-101.
17. Dutta U, Kench J, Byth K, Khan MH, Lin R, Liddle C, et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998;29:1279-84.
18. Tiniakos DG, Brunt EM. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 1999;19:58-68.
19. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis. A prospective study. Gastroenterology 1995;108:812-7.
20. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996;23:1112-8.
21. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997;26:1415-22.
22. Theise ND, Marcelin K, Goldfischer M, Hytiroglou P, Ferrell L, Thung SN. Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 1996;16:134-9.
23. Natarajan S, Theise ND, Thung SN, Antonio L, Paronetto F, Hytiroglou P. Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol 1997;21:312-8.
24. Terris B, Ingster O, Rubbia L, Dubois S, Belghiti J, Feldmann G, et al. Interphase cytogenetic analysis reveals numerical chromosome aberrations in large liver cell dysplasia. J Hepatol 1997;27:313-9.
25. Rubin EM, DeRose PB, Cohen C. Comparative image cytometric DNA ploidy of liver cell dysplasia and hepatocellular carcinoma. Mod Pathol 1994;7:677-80.
26. Cameron RG, Greig PD, Farber E, Wilson S, Sherman M, Levy GA, et al. Small encapsulated hepatocellular carcinoma of the liver. Provisional analysis of pathogenic mechanisms. Cancer 1993;72:2550-9.
27. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,700 men in Taiwan. Lancet 1981;2:1129-33.
28. Beasley RP. Hepatitis B virus. Cancer 1988;61:1942-56.
29. Sakuma K, Saitoh N, Kasai M, Jitsukawa H, Yshino I, Yamaguchi M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988;8:1642-6.
30. Villeneuve J-P, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;108:1000-5.
31. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study of 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990;150:1051-4.
32. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
33. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
34. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;2:463-72.
35. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatitis cirrhosis. Lancet 1989;ii:1004-6.
36. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Prognosis of chronic hepatitis C: result of a large prospective cohort study. Hepatology 1998;28:1687-95.
37. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674-82.
38. Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000;9:213.
39. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13.
40. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000;12:941-8.
41. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-30.
42. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinoma: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
43. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
44. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched controls patients with non-iron related chronic liver disease. Hepatology 2001;33:647-51.
45. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-2.
46. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986;314:736-9.
47. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998;22:742-8.
48. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996;8:989-94.
49. Cohen C, Derose PB. Liver cell dysplasia in alpha-1-antitrypsin deficiency. Mod Pathol 1994; 7:31-6.
50. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh Class A cirrhosis. Am J Med 1996;171:422-34.
51. Collier J, Krahn M, Sherman M. A cost-benefit analysis of the benefit of screening for hepatocellular carcinoma in hepatitis B carriers. Hepatology 1999;30:481A.
52. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost utility analysis. Am J Gastroenterol 2003;98:679-90.
53. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. New York: Grune & Stratton; 1984. p. 209-24.
54. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64.
55. Kew MC, Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology 1988;94:439-42.
56. Kew MC, Marcus R, Geddes EW. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. S Afr Med J 1977;51:306-9.
57. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
58. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
59. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
60. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
61. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
62. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2001;87:741-9.
63. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653-9.
64. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
65. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
66. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.
67. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20:65-71.
68. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, et al. R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol 2000;95:1036-40.
69. Sherman M. Alpha-fetoprotein an obituary. J Hepatol 2001;34:603-5.
70. Seregni E, Botti C, Bombardieri E. Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res 1995;15:1491-9.
71. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. H. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
72. Ajdukiewicz AB, Kelleher PC, Krawitt EL, Walters CJ, Mason PB, Koff RS, et al. Alphafetoprotein glycosylation is abnormal in some hepatocellular carcinoma, including white patients with a normal alpha-fetoprotein concentration. Cancer Lett 1993;74:43-50.
73. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001;16:105-11.
74. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001;16:1378-83.
75. Wang SS, Lu RH, Lee FY, Chao Y, Huang YS, Chen CC, et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996;25:166-71.
76. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 1995;42:387-93.
77. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxy prothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990;11:481-8.
78. Ishizuka H, Nakayama T, Matsuoka S, Gotoh I, Ogawa M, Suzuki K, et al. Prediction of the development of hepatocellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 1999;38:927-31.
79. Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, et al. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer 1998;83:2468-74.
80. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-21.
81. Grazie GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma with special reference to the des-gammacarboxy prothrombin. Liver Transpl Surg 1995;1:249-55.
82. Tangkijvanich P, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health 1999;30:110-4.
83. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108-10.
84. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rates of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-66.
85. Yoshino M. Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol 1983;13:45-52.
86. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. Six-month versus 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78-82.
87. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44.
88. Coakley FV, Schwartz LH. Imaging of hepatocellular carcinoma: a practical approach. Semin Oncol 2001;28:460-73.
89. Dodd GD, Miller WJ, Baron RL, Skolnick ML, Campbell WL. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. Am J Roentgenol 1992;159:727-33.
90. Ueda K, Matsui O, Kawamori Y, Kadoya M, Yoshikawa J, Gabata T, et al. Differentiation of hypervascular hepatic pseudolesions from hepatocellular carcinoma: value of single-level dynamic CT during hepatic arteriography. J Comput Assist Tomogr 1998;22:703-8.
91. Kim TK, Choi BI, Han JK, Chung JW, Park JH, Han MC. Nontumorous arterioportal shunt mimicking hypervascular tumor in cirrhotic liver: two-phase spiral CT findings. Radiology 1998;208:597-603.
92. Yu JS, Kim KW, Sung KB, Lee JT. Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging. Radiology 1997;203:737-42.
93. Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999;30:1174-8.
94. Krinsky GA, Theise Ndrofsky NM, Mizrachi H, Tepperman LW, Weinreb JC. Dysplastic nodules in cirrhotic liver: arterial phase enhancement at CT and MR imaging-a case report. Radiology 1998;209:461-4.
95. Kamura T, Kimura M, Sakai K, Ichida T, Seki H, Yamamoto S, et al. Small hypervascular hepatocellular carcinoma versus hypervascular pseudolesions: differential diagnosis on MRI. Abdom Imaging 2002;27:315-24.
96. Jeong YY, Mitchell DG, Hann HW, Malin AK, Kang HK, Holland GA, et al. Small (< 20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am J Roentgenol 2002;178:1327-34.
97. Oi H, Murakami T, Kim T, Matsushita M, Kishimoto H, Nakamura H. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. Am J Roentgenol 1996;166:369-74.
98. Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445-54.
99. Chen WP, Chen JP, Tsai JW, Chen JS, Hung SW, Su YG, et al. Spectrum of transient hepatic attenuation differences in biphasic helical CT. Am J Roentgenol 1996;172:419-24.
100. Takayasu K, Furukawa H, Wakao F, Muramatsu Y, Abe H, Terauchi T, et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. Radiology 1995;194:101-5.
101. Miller WJ, Baron RL, Dodd GD, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994;193:645-50.
102. Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N. Cirrhosis or chronic hepatitis: evaluation of small (< or = 2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003;226:550-5.
103. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fineneedle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994;20:117-21.
104. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889-93.
105. Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 2001;234:206-9.